European regulators fortify single-arm trial advice, but underscore preference for placebo-controlled designs
The European Medicines Agency has solidified its recommendations to drugmakers that want to use single-arm designs in a pivotal trial, but emphasized that any such …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
